拉米夫定序贯/联合阿德福韦酯治疗慢性乙型肝炎79例疗效分析  

Efficacy analysis of lamivudine and sequential or combined in treatment of 79patients with chronic hepatitis B

作　　者：龙云升[1] 罗林[1] 

机构地区：[1]广东省信宜市人民医院感染科,广东信宜525300

出　　处：《中国医药科学》2014年第13期61-63,117,共4页China Medicine And Pharmacy

摘　　要：目的：探讨拉米夫定序贯/联合阿德福韦酯治疗慢性乙型肝炎的临床疗效。方法选取我院2011年1月-2013年1月收治的慢性乙型肝炎患者79例，随机分为序贯组（40例）和联合组（39例），两组均常规予以保肝治疗，序贯组予以拉米夫定序贯阿德福韦酯进行治疗，联合组予以拉米夫定联合阿德福韦酯进行治疗，比较分析两组的临床疗效。结果联合组用药12个月和24个月时的肝功能指标改善程度显著优于序贯组（P＜0.05）；两组HBeAg、HBV DNA转阴率无明显差异（P＞0.05），HBV DNA定量显著低于序贯组（P＜0.05）；联合组用药12个月、24个月的拉米夫定耐药突变率分别为10.3%、2.6%，显著低于序贯组的35.0%、20.0%（P＜0.05）；两组阿德福韦酯的耐药突变率无明显差异（P＞0.05）。结论拉米夫定联合阿德福韦酯片治疗慢性乙型肝炎具有显著疗效，耐药率低，值得进一步研究应用。Objective To investigate the clinical efficacy of lamivudine and adefovir sequential or combined in treatment of chronic hepatitis B.Methods 79 patients with chronic hepatitis B in our hospital between January 2011 and January 2013 were randomly divided into sequential group （40 cases） and the combination group （39 cases）, both groups were received routine liver treatment.the sequential group received lamivudine adefovir sequential treatment, the combination group received lamivudine combined adefovir treatment. The clinical efficacy of the two groups was comparative analysised.ResultsThe degree of improvement in liver function in combination group for 12 months and 24 months were significantly better than the sequential group （P〈0.05）; HBeAg abd HBV DNA negative rate in two groups was no significant difference （P〉0.05）, HBV DNA quantification was significantly lower than the sequential group （P〈0.05）; combined group treatment for 12 months, the rate of lamivudine resistance mutations 24 months was 10.3%, 2.6%, respectively, significantly lower than the 35.0% sequential group, 20.0% （P〈0.05）; resistant mutation rate of adefovir dipivoxil groups had no significant difference （P〉0.05）.ConclusionLamivudine combined with adefovir dipivoxil tablets in the treatment of chronic hepatitis B have a significant effect and low resistance, it＇s worthy of further research.

关 键 词：拉米夫定 性慢性乙型肝炎 治疗效果 

分 类 号：R512.62[医药卫生—内科学]